
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is demonstrating strong potential for growth and success in the near future due to their innovative product offerings and strategic partnerships in the healthcare industry. Their financial losses are being offset by recent fundraising and the potential for Medicare coverage, and they have multiple key drivers for growth such as expanding into the LBM market and increasing sales rep efficiency. While there are potential risks to their rating and price target, Lucid's positive reception in the medical community and potential for increased collections make it a promising investment opportunity.
Bears say
Lucid Diagnostics is facing challenges in commercializing its products due to a small sales force and slow progress in expanding test volumes. The delay in Medicare coverage is a major concern, as it could limit revenue generation and have an adverse effect on the business. Additionally, while the company's products have potential, there are still risks related to reimbursement and commercial execution. With a relatively low price target of $2.50, the negative outlook is based on the company's current operating level and potential for delays in revenue generation.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares